Quintiles, the world’s leading bio pharmaceutical services company, and London Genetics, an expert in the use of pharmacogenetics in drug discovery and development, today announced a strategic alliance to offer the bio pharmaceutical industry innovative pharmacogenetics solutions to advance personalized medicine. Financial terms were not disclosed.
Thomas Wollman, Senior Vice President, Quintiles Global Central Laboratories said, In the New Health, bio pharmaceutical companies are under relentless pressure to replenish their product pipelines and deliver safer, more effective medicines to patients in need. Through our alliance with London Genetics, we have world-class expertise to help early adopters of personalized medicine use genomic technologies to improve drug discovery and development, and a networked infrastructure to support those efforts virtually anywhere in the world.
Dominique Kleyn, CEO of London Genetics said, Our expertise in pharmacogenetic strategy development combined with Quintiles’ expertise and infrastructure in biomarker development gives biopharma companies a powerful ally in harnessing the value of genomic data for drug development. Ultimately, our alliance will support biopharma in their interactions with academic partners and in the development of personalized medicines.